Dosing & Uses
Neuroendocrine Tumors
Pending FDA approval for pancreatic and nonpancreatic advanced neuroendocrine tumors (NET)
Next:
Pharmacology
Mechanism of Action
Angio-immuno kinase inhibitor that selectively inhibits tyrosine kinase activity associated with vascular endothelial growth factor receptor (VEGFR) and fibroblast growth factor receptor (FGFR)
Previous
Next:
Images
No images available for this drug.
Previous
Next:
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.
